3.29
前日終値:
$3.28
開ける:
$3.3
24時間の取引高:
3.19M
Relative Volume:
0.81
時価総額:
$716.89M
収益:
$35.54M
当期純損益:
$-59.14M
株価収益率:
-9.0459
EPS:
-0.3637
ネットキャッシュフロー:
$-80.19M
1週間 パフォーマンス:
-4.64%
1か月 パフォーマンス:
+1.54%
6か月 パフォーマンス:
-39.52%
1年 パフォーマンス:
+55.19%
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
CTMX
Cytomx Therapeutics Inc
|
3.29 | 716.89M | 35.54M | -59.14M | -80.19M | -0.3637 |
|
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | アップグレード | JP Morgan | Neutral → Overweight |
| 2026-01-20 | 開始されました | Guggenheim | Buy |
| 2025-09-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2025-05-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 再開されました | Piper Sandler | Overweight |
| 2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
| 2021-11-15 | 開始されました | BTIG Research | Buy |
| 2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 開始されました | JP Morgan | Overweight |
| 2021-03-23 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-11-26 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-15 | 開始されました | Goldman | Neutral |
| 2018-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2018-06-01 | 開始されました | SunTrust | Buy |
| 2018-01-05 | 開始されました | Citigroup | Buy |
| 2017-09-08 | 開始されました | Wedbush | Outperform |
| 2017-03-27 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - MarketBeat
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
CytomX Therapeutics (CTMX) Stock Faces Revenue Collapse As Pipeline Hopes Carry The Story - Sahm
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Buy" by Brokerages - MarketBeat
CytomX Therapeutics (NASDAQ:CTMX) Announces Earnings Results - MarketBeat
CytomX Therapeutics, Inc. Stock 12‑Month Price Target Cut to $12.38, Implies 267% Upside - TradingView
State Street Corporation (CTMX) reports 5.4% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlight - GuruFocus
CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ... - Yahoo Finance
CytomX Therapeutics secures $37M from Regeneron amid Q2 revenue miss - scanx.trade
CytomX Q2 2026 Earnings: Revenue Falls as R&D Spending Rises - TradingKey
CytomX Therapeutics Q2 Earnings Call Highlights - marketbeat.com
CTMX Looks 1148.1% Overvalued on GF Value™ - GuruFocus
Earnings call transcript: CytomX misses Q2 2026 estimates as cash runway extends - Investing.com
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Is CytomX Therapeutics Inc (CTMX) Facing Financial Headwinds Aft - GuruFocus
CytomX Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update - The Manila Times
CytomX enrolls 113 patients; next colorectal cancer trial planned - Stock Titan
CytomX Therapeutics posts Q2 2026 results — $1.4M revenue, $25.2M operating expense, $330.3M cash - TradingView
CytomX Therapeutics 2Q 2026: Revenue $1.42M, EPS $(0.09) — 10-Q Summary - TradingView
CytomX Therapeutics, Inc. (CTMX) awards 450,000 options and 100,000 RSUs to CLO - Stock Titan
CytomX Therapeutics, Inc. (CTMX) Chief Legal Officer files Form 3 insider report - Stock Titan
Bank of America (NYSE: BAC) discloses 7.0% ownership stake in CytomX (CTMX) - Stock Titan
CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - The Manila Times
Press Release: CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer - Moomoo
DV Trading LLC Makes New $3.36 Million Investment in CytomX Therapeutics, Inc. $CTMX - MarketBeat
BlackRock, Inc. Adds to CytomX Therapeutics Inc (CTMX) Stake -- Shares Look 1007% Overvalued on GF Value - GuruFocus
Form 4 CytomX Therapeutics Inc For: 31 July By Investing.com - Investing.com Nigeria
CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026 - The Manila Times
CytomX Therapeutics Announces Date for Second Quarter 2026 Financial Results Conference Call - Quiver Quantitative
Ally Bridge Group NY LLC Makes New $4.23 Million Investment in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics, Inc. $CTMX Stake Lifted by Elmind Capital LP - MarketBeat
BlackRock (CTMX holder) discloses 7.6% beneficial stake in CytomX Therapeutics - Stock Titan
CytomX appoints Charles Fuchs to board of directors By Investing.com - Investing.com South Africa
CytomX Therapeutics Inc (CTMX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors - The Manila Times
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
Cytomx Therapeutics Inc (CTMX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chu Yu-Waye | Chief Medical Officer |
Mar 17 '26 |
Sale |
6.42 |
21,279 |
136,675 |
189,446 |
| McCarthy Sean A. | CEO |
Mar 17 '26 |
Sale |
6.42 |
118,969 |
764,138 |
1,078,922 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 17 '26 |
Sale |
6.42 |
31,492 |
202,273 |
300,760 |
| Ogden Christopher | Chief Financial Officer |
Mar 17 '26 |
Sale |
6.42 |
19,323 |
124,112 |
296,948 |
| McCarthy Sean A. | CEO |
Nov 06 '25 |
Sale |
4.54 |
101,793 |
461,906 |
987,891 |
大文字化:
|
ボリューム (24 時間):